New drug cocktail aims to put mantle cell lymphoma into deep remission
NCT ID NCT05951959
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and rituximab—in 108 people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood (MRD-negative) after about a year. Those who achieve this may stop some drugs and be monitored, with the option to restart treatment if needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib, venetoclax, and rituximab (drug combination)
What this could lead to
If successful, this could offer a way to achieve deep remission and allow some patients to stop treatment temporarily, reducing side effects from long-term therapy.
What could go wrong
This is an early-phase trial with only 108 participants, so results may not apply to all patients. The combination may cause serious side effects, and not everyone will achieve remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Porto Alegre, 90035-003, Brazil
-
Research Site
Rio de Janeiro, 22061-080, Brazil
-
Research Site
São Paulo, 01401-002, Brazil
-
Research Site
São Paulo, 05403-010, Brazil
-
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Research Site
Vancouver, British Columbia, V5Z 4E6, Canada
-
Research Site
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Research Site
Barrie, Ontario, L4M 6M2, Canada
-
Research Site
Toronto, Ontario, M5G 2M9, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Gdynia, 81-519, Poland
-
Research Site
Krakow, 30-727, Poland
-
Research Site
Warsaw, 02-781, Poland
-
Research Site
Madrid, 28041, Spain
-
Research Site
Birmingham, B9 5SS, United Kingdom
-
Research Site
Gloucester, GL1 3NN, United Kingdom
-
Research Site
London, SW3 6JJ, United Kingdom
-
Research Site
Norwich, NR4 7UY, United Kingdom
-
Research Site
Nottingham, NG5 1PB, United Kingdom
-
Research Site
Plymouth, PL68BQ, United Kingdom
-
Research Site
Hackensack, New Jersey, 07601, United States
-
Research Site
Stony Brook, New York, 11794, United States
-
Research Site
Cleveland, Ohio, 44195, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Heidelberg, 3084, Australia
-
Research Site
Kogarah, NSW 2217, Australia
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Sydney, 2109, Australia